Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Devinska Nova Ves – page 35

1 098 clinical trials in Devinska Nova Ves, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Devinska Nova Ves at a glance
1 098
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 098 trials in Devinska Nova Ves

Open in trial search

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:EXPD-101
  • Sponsor:Expedition Therapeutics Inc.

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ataciguat
  • Sponsor:Kardigan Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Devinska Nova Ves

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Innovative research focusing on lipoprotein reduction and its impact on major cardiovascular events in patients with established heart conditions. Clinical trials are evaluating new therapeutic approaches to reduce cardiovascular risks.

  • Cardiovascular Death Prevention
  • Heart Attack Risk Reduction
  • Stroke Prevention Strategies

Studies aim to advance treatment options for patients with elevated cardiovascular risk factors.

02 Atrial Fibrillation Management

Ground-breaking research comparing the effectiveness of novel anticoagulants in preventing stroke and systemic embolism in patients with atrial fibrillation. These trials focus on developing safer treatment options.

  • Stroke Prevention
  • Blood Clot Prevention
  • Bleeding Risk Assessment

Investigations seek to establish superior treatment protocols for managing irregular heartbeat conditions.

03 Atherosclerotic Disease Treatment

Comprehensive studies evaluating innovative medications for both primary and secondary prevention of atherosclerotic cardiovascular disease. Research focuses on reducing major adverse cardiovascular events.

  • Vascular Disease Management
  • Coronary Event Prevention
  • Cardiovascular Risk Reduction

These trials aim to establish new standards in preventing cardiovascular complications in high-risk populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.